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“Boiogito” is a Kampo preparation which has been used since ancient times in patients with obesity of the “asthenic constitution”
type, so-called “watery obesity”, and its eﬀect has been recognized clinically. In this study, we investigated the anti-obesity eﬀect
of Boiogito in the TSOD (Tsumura Suzuki Obese Diabetes) mouse, a model of spontaneous obese type II diabetes mellitus.
Boiogito showed a signiﬁcant anti-obesity eﬀect in TSOD mice by suppressing body weight gain in a dosage-dependent manner.
In addition, Boiogito showed signiﬁcant ameliorative eﬀects on features of metabolic syndrome such as hyperinsulinemia, fasting
hyperglycemia and abnormal lipid metabolism. Regarding lipid accumulation in TSOD mice, Boiogito showed a signiﬁcant
suppressive eﬀect on accumulation of subcutaneous fat, but the eﬀect on the visceral fat accumulation that constitutes the basis
of metabolic syndrome was weak, and the suppressive eﬀect on insulin resistance was also weak. Furthermore, Boiogito did not
alleviate the abnormal glucose tolerance, the hypertension or the peripheral neuropathy characteristically developed in the TSOD
mice. In contrast, in the TSNO (Tsumura Suzuki Non-Obesity) mice used as controls, Boiogito suppressed body weight gain and
accumulationofsubcutaneous andvisceralfat.The aboveresults suggested thatBoiogitoiseﬀective asananti-obesity drugagainst
obesity of the “asthenic constitution” type in which subcutaneous fat accumulates, but cannot be expected to exert a preventive
eﬀect against various symptoms of metabolic syndrome that are based on visceral fat accumulation.
1.Introduction
Visceral fat accumulation is considered to induce insulin
resistance and has been proposed as the cause of the so-
called “metabolic syndrome” (MS), a major risk factor for
the ischemic cardiac and cerebrovascular diseases that rank
high as causes of death [1, 2]. At present, it is said that in the
Japanese population aged 40 years old or more, one of two
males and one of ﬁve females are MS patients or would-be
MS patients; thus the importance of MS prevention has been
re-realized [3].
In Kampo medicine, which originated in China in an-
cient times and was developed uniquely in Japan, the so-
called “Obesity” is also treated; preparations prescribed in-
clude Daisaikoto, Saikokaryukotuboreito, Tokakujokito, Da-
iobotanpito, Bofutsushosan, Tudosan, Kumibinroto, Boiog-
ito, and so forth, [4]. In general, obesity falls into two broad
categoriesdepending onitscause. InWestern medicine, obe-
sity is classiﬁed into two types characterized by either vis-
ceral or subcutaneous fat accumulation. On the other hand,
in Kampo medicine, obesity is classiﬁed into the “robust
constitution”-type and the “asthenic constitution”-type. In
Western medicine, the obesity causing MS is of the vis-
ceral fat accumulation type, corresponding to obesity of
the “robust constitution” type (otherwise known as “ﬁrm
obesity”) in Kampo medicine. Of the above Kampo pre-
scriptions, Daisaikoto and Bofutsushosan are used for the
high physical energy type obesity, that is, obesity of the
“robust constitution” type, and we have already reported
thatDaisaikotoandBofutsushosanhaveaneﬀecton“visceral
fat accumulation type” obesity and show a preventive eﬀect
on various metabolic disorders such as abnormal lipid
metabolism, hyperinsulinemia, insulin-resistant hyperten-
sion and peripheral neuropathy [5, 6]. In this study we2 Evidence-Based Complementary and Alternative Medicine
Table 1: The ingredients of Boiogito formula
Crude drugs Weight ratio (g)
Astragalus mongkohcus Bunge 5.0
Sinomenium acutum Rehder et Wilson 5.0
Atractylodes lancea De Candolle 3.0
Zizyphusjujube Miller var. inermis Rehder 3.0
Glycyrrkiza uralensis Fisher 1.5
Zibgiber ojﬁcinale Roscoe 1.0
investigated the preventiveeﬀect of Boiogito, which has been
prescribed for obesity of the “asthenic constitution” type,
on obesity and various metabolic diseases in the TSOD
(Tsumura Suzuki Obese Diabetes) mouse [7–11], a model
of spontaneous obese type II diabetes mellitus. TSOD mice
wereestablishedasamulti-geneobesetype-IIdiabetesmodel
by selecting individual animals that developed obesity and
diabetes from among ddY mice and repeating brother-sister
inbreeding using the body weight and male urinary glucose
level as indices.
2.Subjectsand Methods
2.1. Experimental Animals. Male TSOD mice were used as a
model of spontaneous obese type II diabetes mellitus, and
male TSNO (Tsumura Suzuki Non Obesity) mice were used
as controls. The TSOD and TSNO mice aged 3 weeks (20
animals each) were purchased from the Institute for Animal
Reproduction (Ibaragi Prefecture). The animals were kept
in a dedicated animal room under controlled conditions
(temperature: 23 ± 2◦C, humidity: 55 ± 10%, light on for
12handoﬀfor12hperda y).After1w eekofacclimation,the
experiment was started. During the acclimation period, the
animalsweregivenPowderFeedMF(OrientalYeast Co.,Ltd)
andwateradlibitum,butthenormalfeedwasswit c hedt othe
test feed from the age of 4 weeks. The test feed, prepared by
mixing the normal feed with Boiogito, was givenfor 8 weeks.
All the animal experiments were performed in compliance
with the rules for animal experimentation established at
Musashino University.
2.2. Test Drug. The Boiogito extract powder was supplied by
Tsumura & Co. (Tokyo). This herbal prescription in Table 1
was added to water of 10 times of its quantity and extracted
at 100◦C for 1h. The extract was ﬁltered and spray-dried
to obtain the dry extract powder. Figure 1 shows the 3D
HPLC chart oftheBoiogito extract powder. The testfeed was
prepared by mixing the normal feed, Powder Feed MF, with
the Boiogito extract powder thoroughly so that the uniform
concentration of Boiogito was 1.0% or 3.0%.
2.3.Modeof Administration. After 1week of acclimation, the
TSOD and TSNO mice aged 4 weeks were weighed and
grouped so that the body weight distribution was not
markedly diﬀerent among the groups. The control groups
were given Powder Feed MF ad libitum,a n dt h ed r u gt r e a t -
ment groups were given the feed containing 1.0% Boiogito
(low-dosage group) or the feed containing 3.0% Boiogito
(high-dosage group) ad libitum.
2.4. Body Weight Gain and Feed Intake. The body weight was
measured once a week. The feed intake was measured from 1
weekafterstartingtheexperimentandcalculatedasthemean
daily value in each cage by deducting the remaining feed
amount and the spilled feed amount from the feed amount
ﬁlled into the feed container on the day before and dividing
the diﬀerence by the number of animals in the cage.
2.5. Determination of Amounts of Visceral and Subcutaneous
Fat. At 8 weeks after starting administration of the test feed
(at the age of 12 weeks), each mouse was anesthetized with
Nembutal (50mg/kg, i.p.) and placed within computerized
tomography (X-ray CT) equipment used for experimental
animals (La Theta, Aloka Co., Ltd, Tokyo). The amounts
of visceral and subcutaneous fat were determined for the
whole body and at individual sites by scanning at intervals
of 1.5mm.
2.6.BloodBiochemicalTests. At8 weeksafterstarting admin-
istration of the test feed (at the age of 12 weeks), each mouse
was subjected to blood sampling from the orbital cavity
venous plexus under non-fasting conditions without anes-
thesia. This blood was centrifuged to obtain plasma; blood
glucose, total cholesterol (TC)and triacylglycerol (TG)levels
were determined using biochemical test kits (Wako Pure
Chemical Industries, Ltd. Osaka) and the insulin level was
assayed using Rebis Insulin-Mouse-T (ELISA Insulin Kit,
Shibayagi Co., Ltd., Tokyo).
2.7. Glucose Tolerance Test. At 8 weeks after starting admin-
istration of the test feed (at the age of 12 weeks), each mouse
wasmadetofastforatleast18handthenglucosewasadmin-
isteredorally(2g/kg).Bloodsamplesweretakenimmediately
before administration of glucose and at 30, 60, 120 and
180min after administration of glucose from the orbital
cavity venous plexus. The blood taken was centrifuged to
obtain the plasma, followed by determination of plasma glu-
cose levels.
2.8. Blood Pressure. At 8 weeks after starting administration
of the test feed (at the age of 12 weeks), each mouse was
restrained in a restraint device (THC-2, Softron Co., Ltd,
Tokyo), and the body temperature was maintained at 37◦C.
The tail was inserted (up to the base) into the tail cuﬀ of
a non-invasive blood pressure meter (BP-98A, Softron Co.,
Ltd.)todeterminethesystolicbloodpressure, diastolicblood
pressure and mean blood pressure.
2.9. Pain Test. The peripheral neuropathy was determined
using the foot pinch method reported by Suzuki et al. [12].
At 8 weeks after starting administration of the test feed (at
the age of 12 weeks), the proximal tarsal part of the hind
limb metatarsal region was clipped with an artery clamp
(BHO20R, pressure: 300g, Bulldog Clamp, Johns Hopkins,
Tokyo), and the time until the mouse bit the clamp onEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Analysis by three-dimensional HPLC of major chemical compounds included in Boiogito extracts.
the hind limb was measured as the latent time to response.
The average of the latent time values of the two hind limbs
was considered to be the latent time ofthe mouse concerned.
2.10. Statistical Processing. In each experiment, the inter-
group diﬀerence was tested for signiﬁcance by Dunnett’s
multiple comparison with a signiﬁcance level of 5%.
3.Results
3.1. Body Weight Gain and Feed Intake. Figure 2 shows the
body weight gains in the TSOD and TSNO mouse groups.
Thebody weightgain was higher intheTSODmouse control
group than in the TSNO mouse control group from the start
of the experiment, and the TSOD mice were obese. In the
TSOD mouse groups, the body weight gain was signiﬁcantly
suppressed in the Boiogito low-dosage group from 4 weeks
after starting the experiment and in the Boiogito high-
dosagegroupfromimmediatelyafterstarting theexperiment
as compared with the control group. In the TSNO mouse
group, the body weight gain was signiﬁcantly suppressed in
both the low- and high-dosage groups from around 4 weeks
after starting the experiment.
The feed intake was higher in the TSOD mouse groups
than in the TSNO mouse group throughout the experiment
period but no signiﬁcant diﬀerence was seen between any
two TSOD mouse groups and between any two TSNO
mouse groups (feed intake at the age of 6 weeks: 3.5 ±
0.2g/day/body in the TSNO control group, 3.4 ± 0.6
g/day/body in the TSNO Boiogito low-dosage group and
3.3 ± 0.3g/day/body in the TSNO Boiogito high-dosage
group; 4.3 ± 0.1g/day/body in TSOD control group, 3.8 ±
0.6g/day/body in the TSOD Boiogito low-dosage group and
4.3 ± 0.4g/day/body in the TSOD Boiogito high-dosage
group)
3.2. Changes in Amounts of Visceral and Subcutaneous Fat.
Figure 3(a) shows the total visceral and subcutaneous fat at
8 weeks after starting the experiment, and Figure 3(b) shows
the by-site accumulation status of visceral fat and subcu-
taneous fat. As clearly seen in Figure 3(a), total visceral fat
and total subcutaneous fat accumulated signiﬁcantly more
in the TSOD mouse control group than in the TSNO mouse
control group. In the TSOD mouse groups, the Boiogito
treatment did not inﬂuence the total amount of visceral fat
but signiﬁcantly suppressed accumulation of subcutaneous
fat. As shown in Figure 3(b), which shows the by-site
accumulation of subcutaneous fat 8 weeks after starting the
experiment, Boiogito caused dose-dependent suppression of
accumulation of subcutaneous fat around the scapula and4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀect of Boiogito on the body weight in mice. Filled
diamond: TSOD control, ﬁlled square: TSOD Boiogito 1%, ﬁlled
triangle: TSOD Boiogito 3%, open diamond: TSNO control, open
square: TSNO Boiogito 1%, open triangle: TSNO Boiogito 3%.
Datarepresent the mean ± SDofﬁveto sevenanimals. ∗P < .05 and
∗∗P < .01 signiﬁcantly diﬀers from the TSOD control group. #P <
.05, ##P < .01, signiﬁcantlydiﬀers from the TSNO control group.
hipjoint,and asigniﬁcantdiﬀerencewasseenintheBoiogito
high-dosage group. Conversely, in the TSNO mouse groups,
a signiﬁcant suppressive eﬀect was seen on accumulation of
total visceral fat, total subcutaneous fat, by-site visceral fat
and by-site subcutaneous fat in both the Boiogito low- and
high-dosage groups.
3.3. Blood Biochemical Tests. Table 2 shows blood biochemi-
cal test values in the TSOD mouse groups and TSNO mouse
groups at the time of completing the experiment.
The fasting blood glucose level, TC level and insulin level
were higher in the TSOD mouse control group than in the
TSNOmouse controlgroup.IntheTSODmouse groups, the
TC and TG levels were suppressed in the Boiogito treatment
groups in a dosage-dependent manner, and the diﬀerence
from the control group was signiﬁcant for TC level in the
high-dosage group and for TG level in both the low- and
high-dosage groups. There were no changes in blood glucose
level after feed intake related to Boiogito treatment, but the
fasting blood glucoselevelwas signiﬁcantly lower in both the
Boiogito low- and high-dosage groups than in the control
group. The insulin level was lower only in the Boiogito low-
dosage group. Conversely, in the TSNO mouse group no
parameter changed in relation to Boiogito treatment.
3.4. Glucose Tolerance Test. At 8 weeks after starting admin-
istration of thetestfeed, each mousewas madeto fast for one
night and then given glucose orally (2g/kg). From the time-
course changes in blood glucose level up to 180min after
glucose administration, the “Glucose area under the con-
centration curve” (AUC) was calculated. Table 3 shows the
results.TheAUCwassigniﬁcantlyhigherintheTSODmouse
control groupthanin theTSNOmouse control group. There
was no marked diﬀerence from the control group in either
the TSOD mice or TSNO mice treated with Boiogito.
3.5.BloodPressure. Table 4 showsthesystolicbloodpressure,
diastolic blood pressure and mean blood pressure in each
g r o u po ft h eT S O Da n dT S N Om i c e .
The systolic blood pressure, diastolic blood pressure and
mean blood pressure were signiﬁcantly higher in the TSOD
mouse control group than in the TSNO mouse control
group. In boththe TSODmice and TSNOmice, the Boiogito
treatment had no substantial inﬂuence on systolic blood
pressure, diastolic blood pressure or mean blood pressure.
3.6. Pain Test. Figure 4 shows the pain test results in each
group of TSOD mice and TSNO mice.
Thelatenttimetoresponse wassigniﬁcantlylongerinthe
TSODmousecontrolgroupthanintheTSNOmousecontrol
group. It was conﬁrmed that the TSODmouse control group
developed neuropathy. In both the TSOD mice and TSNO
mice, the Boiogito treatment had no substantial inﬂuence on
latent time to response.
4.Discussion
In recent years, the number of obese people has increased
rapidly due to Westernization of eating habits and develop-
ment of means of transportation, but on the other hand,
excessive dieting for beauty/shape maintenance and various
healthy foods have become popular among females. In
general,obesityisclassiﬁed intothevisceralfataccumulation
type(maletype)andthesubcutaneousfataccumulationtype
(female type) [13], and subsequent disease progression and
therapy are diﬀerent depending on the type. MS highlighted
in the world has been reported to be caused especially by
visceral fat accumulation.
In Kampo medicine, obese patients are divided into the
“robust constitution” type and the “asthenic constitution”
type, and various Kampo preparations tailored to each
type are prescribed. Many obese patients of the “robust
constitution” type have obesity of the so-called “visceral fat
accumulation type” and are generally big-boned, tend to be
constipated, and have a plump lower abdomen. Conversely,
many obese patients of the “asthenic constitution” type
haveobesity oftheso-called “subcutaneousfat accumulation
type” and tend to be fair-skinned, soft-muscled, edema-
tous/obese, and sweat easily [14].
As a part of programs to develop preventive or thera-
peutic drugs against various symptoms of the MS, we have
investigated the eﬀects of Kampo preparations, which have
been used against obesity from ancient times, using multi-
factor genetic TSOD mice that show obesity characterized
by spontaneous accumulation of abdominal and subcuta-
neous fat, and develop various metabolic disorders such as
abnormal glucose/lipid metabolism and hypertension. As
mentioned above, we have already clariﬁed that Daisaikoto
and Bofutsushosan, which are used against obesity of the
“robust constitution” type, show preventive eﬀects against
various symptoms of MS, although eﬀects vary [5, 6]. MSEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of Boiogito on fat accumulation in TSOD and TSNO mice. (a) Total amounts of visceral and subcutaneous fat at 8 weeks
after starting the experiment. (b) By-site accumulation of visceral and subcutaneous fat at 8 weeks after starting the experiment Filled
diamond: TSOD control, ﬁlled square:TSOD Boiogito 1%, ﬁlled triangle: TSOD Boiogito 3%, open diamond: TSNO control, open square:
TSNOBoiogito1%,opentriangle:TSNOBoiogito3%.Datarepresentthemean±SDofﬁvetosevenanimals. ∗P <.05, ∗∗P <.01,signiﬁcant
diﬀerences from the TSOD control group. #P < .05, ##P < .01, signiﬁcant diﬀerences from the TSNO control group.
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Figure 4: The eﬀect of Boiogito on the peripheral neuropathy.
Data represent the mean ± SD of ﬁve to seven animals. ∗P < .05,
signiﬁcantlydiﬀers from the TSOD control group.
is conceived of as a disease state characterized by excessive
energy due to overeating and shortage of exercise and corre-
spondstothe“robustconstitution”typeinKampomedicine,
so the above eﬀects seen with Daisaikoto and Bofutsushosan
make theoretical sense. On the other hand, Boiogito used
in this study is the Kampo preparation described in the
Chineseancientliteratureas“JinKuiyaolue”,which contains
six crude drugs and is used for treatment of obesity of the
“asthenic constitution” type, that is, patients who are fair-
skinned, soft-muscled, edematous (rich in subcutaneous
fat) and easily susceptible to edema [4, 15]. Boiogito was
reported to lower blood glucose in a study using mice with
streptozotocin-induced diabetes [16, 17]. Furthermore, in
ovariectomized rats, Boiogito showed an anti-obesity eﬀect,
and partial involvement of TNFα was suggested as the mech-
anism of action [18].6 Evidence-Based Complementary and Alternative Medicine
Table 2: Eﬀects of Boiogito on biochemical parameters of plasma
TSOD mice TSNO mice
Control 1% 3% Control 1% 3%
Feed-Glucose (mg/dl) 184 ± 41 194 ± 38 159 ± 20 188 ± 33 155 ± 15 164 ± 20
Fast-Glucose (mg/dl) 174 ± 18 121 ± 11∗∗ 139 ± 43∗ 87 ± 12∗∗ 95 ± 99 7 ± 12
TC (mg/dl) 228 ± 448 209 ± 43 172 ± 12∗ 140 ± 18∗∗ 154 ± 12 146 ± 6
TG (mg/dl) 234 ± 28 173 ± 20∗∗ 166 ± 35∗∗ 129 ± 20∗∗ 148 ± 33 151 ± 35
Insulin (ng/ml) 15.8 ± 15.3 2.4 ± 1.6∗ 9.0 ± 7.3 1.5 ± 1.3∗ 2.5 ± 1.9 1.9 ± 0.9
Data represent the mean ± SD of 5–7 animals.
∗P < .05, ∗∗P < .01, signiﬁcantly diﬀerences from the TSOD control group.
Table 3:Eﬀect ofBoiogitoonAUCintheoralglucosetolerancetest
AUC (mg/ml/min) Control Boiogito (1%) Boiogito (3%)
TSOD mice 89.2 ± 16.4 76.2 ± 16.8 75.8 ± 20.1
TSNO mice 61.5 ± 8.4∗ 58.3 ± 3.2 55.1 ± 8.3
Data represent the mean ± SD of 5–7 animals.
∗P < .05, Signiﬁcantlydiﬀerent from the TSOD control group.
In this study, to investigate the preventiveeﬀectof Boiog-
ito on obesity and various metabolic diseases, we used TSOD
mice aged 4 weeks in which obesity and various metabolic
disorders had not yet developed, and TSNO mice were used
as controls. When body weight gain in the TSOD mice
and TSNO mice was compared, the TSOD mice showed
signiﬁcantly higher body weight gain from the start of the
experiment, as reported previously, and apparently develop
obesity. Boiogito suppressed body weight gain from the
early stages of treatment in both the TSOD mouse groups
and TSNO mouse groups. TSNO mice are normal mice
developing no disease, and the suppressive eﬀect of Boiogito
on body weight gain in the TSNO mice (a 10% decrease
in the high-dosage group as compared with the control
group) was comparable with that in the TSOD mice (a
7% decrease in the high-dosage group as compared with
the control group), suggesting that Boiogito shows an anti-
obesity eﬀect or suppressive eﬀect on body weight gain not
only in the obese state but also in the non-diseased (healthy)
state. Since the main cause of obesity is fat accumulation,
visceral and subcutaneous fat accumulations were examined
using X-ray CT, by site. We found that the total visceral and
subcutaneous fat accumulation were signiﬁcantly higher in
the TSOD mouse control group than in the TSNO mouse
control group. The suppressive eﬀects of Boiogito on this
accumulationwere investigated. In the TSODmouse groups,
the suppressive eﬀect was signiﬁcant for total subcutaneous
fat accumulation in the high-dosage group, and in the TSNO
mouse groups, the suppressive eﬀect was signiﬁcant for both
total visceral fat accumulation and total subcutaneous fat
accumulation in both the low- and high dosage groups.
Furthermore, looking at by-site fat accumulation, in the
TSOD mouse groups, Boiogito signiﬁcantly suppressed
subcutaneous fat accumulation around the scapula and hip
joint in a dosage-dependent manner, and in the TSNO
mouse groups, Boiogito signiﬁcantly suppressed both vis-
ceral fat accumulation and subcutaneous fat accumulation
throughout most of the body. These results suggest that the
anti-obesity eﬀect or suppressive eﬀect of Boiogito on body
weight gain is mainly due to the suppression of subcuta-
neous fat accumulation around the scapula and hip joint.
Morishima et al. conﬁrmed a decrease in subcutaneous fat
in subjects given Boiogito [19] coinciding with the eﬀect
of Boiogito on subcutaneous fat accumulation seen in this
study.
We next investigated the eﬀects of Boiogito on the phe-
nomena occurring after visceral fat accumulation such as
insulin resistance, abnormal glucose tolerance, abnormal
lipid metabolism, hypertension, and so forth. The fasting
blood glucoselevel and insulin levelwere signiﬁcantly higher
in TSOD mice than in TSNO mice, on comparison of all
corresponding groups. In TSOD mice, Boiogito treatment
signiﬁcantly suppressed the increase in fasting blood glucose
levels in both the Boiogito low- and high dosage groups
but signiﬁcantly suppressed the increase in insulin levels
only in the low-dosage group. No dosage-dependency was
seen in this suppression, and the Boiogito treatment did
not improve the abnormal glucose tolerance seen in the
glucose tolerance test of the TSOD mice. Furthermore, the
Boiogito treatment did not change the blood glucose level
after feed intake. These results suggest that the eﬀects of
Boiogito on lowering blood glucose and improving insulin
resistance are not potent. On the other hand, in the TSNO
mice, the Boiogito treatment did not inﬂuence fasting blood
glucose levels or insulin levels. As regards lipid metabolism,
the TC level and TG level were signiﬁcantly higher in the
TSOD mice than in the TSNO mice on comparison of
all corresponding groups. Regarding the abnormal lipid
metabolism seen in TSOD mice, the Boiogito treatment
signiﬁcantly decreased the TC level in the high-dosage group
and signiﬁcantly decreased theTG levelin the low-and high-
dosage groups. Of the crude drugs contained in Boiogito,
it is known that a water extract of Zingiber oﬃcinale shows
an inhibitory eﬀect on pancreatic lipases and an anti-obesity
eﬀect [20]; the ethanol extract lowers TG, lipoprotein and
phospholipidlevelsinhyperlipidemicanimals[21]andother
components inhibit cholesterol synthesis in the liver [22]I n
addition, glycyrrhizin, a component of Glycyrrhiza uralensis,
is known to improve hyperglycemia, hyperinsulinemia and
abnormal glucose tolerance, and so forth, with high-dose
administration in KK-Ay mice [23]. Furthermore, Astragalus
mongholicus is known to improve blood glucose proﬁle [17,
18]. It is thus apparent that Z. oﬃcinal, G. uralensis andEvidence-Based Complementary and Alternative Medicine 7
Table 4: The eﬀect of Boiogito on blood pressure in mice
BP (mmHg) TSOD mice TSNO mice
Control 1% 3% Control 1% 3%
Systolic BP 113 ± 12 102 ± 6 111 ± 13 99 ± 5∗ 95 ± 4 102 ± 9
Diastolic BP 78 ± 97 3 ± 57 4 ± 66 9 ± 4∗ 70 ± 57 2 ± 9
Mean BP 90 ± 98 3 ± 58 6 ± 57 9 ± 3∗ 78 ± 58 1 ± 9
Data represent the mean ± SD of 5–7 animals.
∗P < .05, Signiﬁcantlydiﬀerent from the TSOD control group.
BP: Blood pressure.
A. mongholicus contribute greatly to the beneﬁcial eﬀects of
Boiogito on abnormal glucose metabolism and abnormal
lipid metabolism. Since, as mentioned, the eﬀect of Boiogito
on insulin resistance was not potent, we speculate that direct
inhibition of lipid absorption might contribute to the eﬀect
of Boiogito on abnormal lipid metabolism.
Inaddition,Boiogitodidnotshowanyparticularamelio-
rative eﬀects on the hypertension and peripheral neuropathy
that occur in TSOD mice. We speculate that, as noted,
Boiogito did not show a deﬁnite beneﬁcial eﬀect on insulin
resistance, this accounts for the absence of an eﬀect on
consequent symptoms such as hypertension and peripheral
neuropathy.
In the TSNO mouse used as non-diseased model, Boiog-
ito suppressed body weight gain, visceral fat accumulation
and subcutaneous fat, but didn’t inﬂuence the chemical
parameters, abnormal glucose tolerance, blood pressure and
pain test. As indicated above, Z. oﬃcinale,o n ec o m p o n e n t
of Boiogito, shows an inhibitory eﬀect on pancreatic lipases.
Therefore, inhibition of lipid absorption by Z. oﬃcinale
might be a factor in suppression eﬀect of body weight gain.
As mentioned above, Boiogito showed an eﬀect against
obesity, but this eﬀect was mainly attributable to a suppres-
sive eﬀect on subcutaneous fat accumulation. We suggest
that a speciﬁc eﬀect on “visceral fat accumulation type”
obesity cannot be expected and that Boiogito should be used
in females of the “asthenic constitution” type or patients
with “watery obesity” according to the theory of Kampo
medicine.
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